Related Experiment Video
Updated: Jan 1, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Strategy of blood pressure intervention in the elderly hypertensive patients (STEP): Rational, design, and baseline
Shuyuan Zhang1, Shouling Wu2, Jie Ren3
1State Key Laboratory of Cardiovascular Disease, Hypertension Center, FuWai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100037, China.
Insights
The STEP trial investigates intensive versus standard blood pressure treatment targets in older adults with hypertension. It also assesses the effectiveness of smartphone app management for improving blood pressure control.
Area of Science:
- Cardiology
- Geriatrics
- Clinical Trials
Background:
- Optimal systolic blood pressure (SBP) treatment targets for elderly individuals remain a challenge.
- Patient non-adherence is a significant factor contributing to uncontrolled hypertension.
- The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial addresses these issues.
Purpose of the Study:
- To compare the benefits of intensive SBP treatment (110–129 mmHg) versus standard treatment (130–149 mmHg) on cardiovascular events in hypertensive patients aged 60-80 years.
- To evaluate the efficacy of smartphone app-based management in controlling blood pressure compared to usual care.
- To provide evidence for optimal BP control targets and management strategies in the elderly.
Main Methods:
- A multi-center, randomized controlled trial involving 8511 patients with primary hypertension in China.
- Participants were randomized 1:1 to intensive or standard BP treatment groups, stratified by clinical site.
- A secondary objective involved randomizing hospitals to smartphone app or usual care groups to assess app management effectiveness.
- Standardized, validated home and office BP devices with automatic data upload were used.
Main Results:
- The study recruited 8511 patients aged 60-80 years, with a mean age of 66.2 years.
- 24.1% of participants were in the 70-80 year age range.
- 65% of participants were classified as high-risk based on a 10-year Framingham risk score ≥ 15%.
Conclusions:
- The STEP trial will offer crucial evidence regarding the appropriate SBP treatment target for hypertensive individuals aged 60-80 years.
- Findings will inform the development of effective hypertension management models, including the use of mobile health applications.
- The study aims to reduce cardiovascular events by optimizing blood pressure management in the elderly population.
Abstract:
The optimal systolic blood pressure (SBP) treatment target in elderly people is full of challenge, and non-adherence is one major cause of uncontrolled BP. The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial is a multi-center, randomized controlled trial that aims to examine whether an intensive treatment (110 ≤ SBP < 130 mmHg) will provide more benefits in lowering cardiovascular events than a mild treatment (130 ≤ SBP < 150 mmHg) among people aged 60-80 years. From January 10, 2017 to December 31, 2017, 8511 patients with primary hypertension were recruited at 42 clinical centers throughout China and randomly assigned to the intensive or standard treatment in 1:1 ratio, in which clinical sites are considered as a stratification factor in randomization. Participants will be followed for an average of four years. All participants used the same validated home BP device and all centers used the same validated office BP device which can automatically upload the readings to a data center. The hospitals were randomly classified as the smartphone-based App center or usual care center in 1:1 ratio for the secondary purpose to study the effect of App management on BP control. In this trial, mean age of participants was 66.2 ± 4.8 years, 24.1% were in the range of 70-80 years, and 65% were at high-risk with the 10-year Framingham risk score ≥ 15%. In conclusion, STEP will provide evidence not only to address appropriate target of BP control among hypertensive patients aged 60-80 years, but also to assess an effective model of App management for hypertension. Trial Registration number: ClinicalTrials. gov. Unique identifier: NCT03015311.
Related Concept Videos
Hypertension V: Nursing Management
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension I: Introduction
Drug Dosing: Geriatric Patients
Assessment of blood pressure in brachial artery(two-step method)
